Insight

Michael Duruisseaux: Toxicities associated with sequential or combined use of small targeted therapies in lung cancer

Michael Duruisseaux/X

Jul 25, 2024, 15:01

Michael Duruisseaux: Toxicities associated with sequential or combined use of small targeted therapies in lung cancer

Michael Duruisseaux, Thoracic Oncologist at HCL – Hospices Civils de Lyon, shared on X:

“Hot of the press: very pleased to share this team work “Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in lung cancer”.

Led by Thomas Pierret and Dr Desage.”

Source: Michael Duruisseaux/X

Michael Duruisseaux

Authors: Anne-Laure Désage, Michael Duruisseaux, Claire Lafitte, Sophie Bayle-Bleuez, Christos Chouaid. Pierre Fournel, Thomas Pierret

Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature

Anne-Laure Désage cancer Christos Chouaid. Pierre Fournel Claire Lafitte HCL - Hospices Civils de Lyon Lung cancer Michael Duruisseaux OncoDaily Oncology Sophie Bayle-Bleuez Thomas Pierret

10 Caring Notes from Pope Francis on Healthcare

FDA Approves Penpulimab for Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma

Senate President Passes Away After Brave Battle with Cancer: Dominick J. Ruggerio

Where to Study to Become ASCO President: 2025 Institutional Rankings

Yelak Biru: UK grants first approval for Blenrep in multiple myeloma